RxDoctor Payments Data

David Bracciano, DO

MOHS-Micrographic Surgery · University Park, FLNPI 1013970870

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $10,414 of the $14,604 with a category attached, or 71.3%. AbbVie accounts for 80.5% of it on its own, with 26 other manufacturers making up the rest. 2025 is the largest year on record at $3,734, more than ten times the $335 reported in 2019.

$14,604in general payments, 2019–2025

Across 244 payments — averaging $59.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$12K
  • Sun Pharmaceutical Industries Inc.$461
  • Johnson & Johnson$334
  • UCB, Inc.$269
  • Biofrontera Inc.$228
  • Regeneron Healthcare Solutions, Inc.$218
  • plus $1K from 21 others

What the payments were for

  • Speaking & faculty fees$10,41471%
  • Food & beverage$3,63525%
  • Education$5554%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,604 in reported general payments places this provider in the 85th percentile of 141 mohs-micrographic surgery providers in Florida.

See all mohs-micrographic surgery providers in Florida

Medicare billing

Part B allowed, 2024
$998,781
Medicare patients
1,678
Services billed
13,302

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab33$149,163
Cosentyx Sensoready (2 Pens)Secukinumab12$87,481
Triamcinolone Acetonide432$6,188
Ketoconazole384$5,976
Clobetasol Propionate97$4,784
Fluocinonide96$3,222
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip123$2,996
Doxycycline Hyclate195$2,757
Metronidazole53$2,746
Tretinoin11$1,271
Clindamycin Phosphate33$682
Cephalexin50$568
Gentamicin Sulfate20$500
Famciclovir12$483
Mupirocin74$434

Paid to pharmacies, not to this prescriber.

Other mohs-micrographic surgery in University Park

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →